

DATE:	2022 May 16
TO:	All Laboratory Services Pathologists and Technical Staff, AHS Oncologists and Nursing
FROM:	Alberta Precision Laboratories Calgary Gynecologic Subspecialty Leads
RE:	Provincial process for HER2 requests on advanced stage or recurrent endometrial serous carcinoma

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

- A provincial process has been developed to provide direction on the ordering of HER2 for patients with advanced stage or recurrent endometrial serous carcinoma.
- Criteria have been defined to identify which patients and tissues may be eligible for this test.
- Ensure patient and sample identifiers, clinical information and devitalization and fixation times are provided on all requests, as outlined in the provincial process.

Background

- HER2 is used as a predictive marker for patients with Advanced Stage or Recurrent Endometrial Serous Carcinomas including mixed carcinomas with a serous component. Carcinosarcomas are currently ineligible for HER2 testing. Positive results predict a potentially more favorable response to combination Trastuzumab with Carboplatin and Paclitaxel compared to Carboplatin and Paclitaxel alone.
- Herceptin and other HER2 targeted therapies have been found to be effective in treating recurrent or advanced stage Endometrial Serous Carcinomas that are HER2 positive. Clinicians require HER2 testing to access the targeted drugs through director's privilege, similar to Breast and Gastric carcinomas. While the immunohistochemical staining and in situ hybridization testing is similar, there are some differences compared to the breast and gastric cases.

Action Required

- Follow the process for HER2 requests on advanced stage or recurrent endometrial serous carcinoma - refer to [Special Interest Groups \(SIGs\) | Insite \(albertahealthservices.ca\)](#) on AHS Insite under Gynecologic – "***Client Resource - Ordering HER2 on Advanced Stage or Recurrent Endometrial Serous Carcinoma***"

Effective **Immediately**

Questions/Concerns

- Dr. Sandra Lee, Pathologist at 403-956-1380
- Dr. Travis Ogilvie, Pathologist at 403-956-1358

Approved by

- Dr. Cheng-Han Lee, Pathologist, Provincial Gynecologic Subspecialty Group Co-Lead, North Sector
- Dr. Sandra Lee, Pathologist, Provincial Gynecologic Subspecialty Group Co-Lead, South Sector